Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study.

CONCLUSIONS:: Cariprazine, at both 1.5 mg/day and 3.0 mg/day, was effective, generally well tolerated, and relatively safe in reducing depressive symptoms in adults with bipolar I depression. PMID: 30845817 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30845817?dopt=Abstract

Source: The American Journal of Psychiatry - March 7, 2019 Category: Psychiatry Authors: Earley W, Victoria Burgess M, Rekeda L, Dickinson R, Szatmári B, Németh G, McIntyre RS, Sachs GS, Yatham LN Tags: Am J Psychiatry Source Type: research